CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Baillie Gifford & Co.

Baillie Gifford & Co. increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 2.4% in the second quarter, Holdings Channel.com reports. The institutional investor owned 405,425 shares of the company’s stock after purchasing an additional 9,510 shares during the quarter. Baillie Gifford & Co.’s holdings in CRISPR Therapeutics were worth $21,897,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Capital International Investors boosted its stake in shares of CRISPR Therapeutics by 27.8% during the 1st quarter. Capital International Investors now owns 7,837,074 shares of the company’s stock valued at $534,175,000 after buying an additional 1,702,624 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 2.9% in the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after purchasing an additional 46,148 shares during the last quarter. SR One Capital Management LP acquired a new stake in shares of CRISPR Therapeutics in the 1st quarter worth about $71,496,000. Charles Schwab Investment Management Inc. raised its holdings in shares of CRISPR Therapeutics by 2.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock valued at $40,879,000 after buying an additional 15,085 shares during the last quarter. Finally, Norges Bank acquired a new stake in CRISPR Therapeutics in the 4th quarter valued at approximately $38,661,000. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Needham & Company LLC reduced their price objective on shares of CRISPR Therapeutics from $88.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Barclays reduced their price target on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 6th. Truist Financial decreased their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a report on Monday, August 12th. Rodman & Renshaw started coverage on CRISPR Therapeutics in a report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Finally, Stifel Nicolaus decreased their price target on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Trading Up 2.5 %

NASDAQ:CRSP traded up $1.19 during trading hours on Friday, hitting $48.69. 851,675 shares of the stock traded hands, compared to its average volume of 1,566,693. The firm has a market cap of $4.13 billion, a price-to-earnings ratio of -17.90 and a beta of 1.70. The firm has a 50 day moving average price of $54.07 and a 200 day moving average price of $61.63. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. CRISPR Therapeutics’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.98) earnings per share. Research analysts predict that CRISPR Therapeutics AG will post -5.52 EPS for the current year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of CRISPR Therapeutics stock in a transaction on Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.